Status:
RECRUITING
Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD
Lead Sponsor:
Johns Hopkins University
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
ADHD - Combined Type
Eligibility:
All Genders
6-40 years
Phase:
PHASE4
Brief Summary
The investigators' goal is to develop neuroimaging biomarkers to predict response to treatment with methylphenidate, which then can be used in the development of novel pharmacological treatments for a...
Eligibility Criteria
Inclusion
- right handed
Exclusion
- pregnant or breast feeding
- past or current neurological disorder
- non-ADHD cause of cognitive impairment
- uncontrolled medical disorder
- head trauma with loss of consciousness in the last year or any evidence of functional impairment due to and persisting after head trauma
- having an adverse reaction to methylphenidate, or other stimulant medication
- having a contraindication to MRI
- current smoking
Key Trial Info
Start Date :
July 27 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2029
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04781972
Start Date
July 27 2021
End Date
April 30 2029
Last Update
October 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins School of Medicine
Baltimore, Maryland, United States, 21205